Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m(2), i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; s...
Purpose: In the last years, fludarabine (FLU) alone or in combination with other drugs has been repo...
The current study was conducted to asses the safety profile and clinical activity of rituximab in co...
Indolent non-Hodgkin lymphomas (iNHLs) are B-cell neoplasms for which no consensus is available abou...
Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has b...
Introduction: INFL comprises a rather heterogeneous subgroup of lymphomas,including small lymphocyti...
BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...
BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...
In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to b...
Fludarabine, a purine nucleoside analog, is currently indicated for the first-line treatment of chro...
Both Cyclophsphamide (C) and Fludarabine (F) have individual anti-lymphoma activity and the combinat...
In recent years, conventional dose of fludarabine (FLU) alone or in combination with other drugs has...
The fludarabine plus cyclophosphamide (FC) regimen was reported to be superior to chlorambucil or fl...
Background: Fluadarabine (FLU) is a new antimetabolite chemotherapeutic agent with a promising thera...
BACKGROUND: Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with a promising therap...
BACKGROUND. A prospective, single-arm, open-label, nonrandomized Phase 2 study of combined fludarabi...
Purpose: In the last years, fludarabine (FLU) alone or in combination with other drugs has been repo...
The current study was conducted to asses the safety profile and clinical activity of rituximab in co...
Indolent non-Hodgkin lymphomas (iNHLs) are B-cell neoplasms for which no consensus is available abou...
Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has b...
Introduction: INFL comprises a rather heterogeneous subgroup of lymphomas,including small lymphocyti...
BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...
BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell pro...
In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to b...
Fludarabine, a purine nucleoside analog, is currently indicated for the first-line treatment of chro...
Both Cyclophsphamide (C) and Fludarabine (F) have individual anti-lymphoma activity and the combinat...
In recent years, conventional dose of fludarabine (FLU) alone or in combination with other drugs has...
The fludarabine plus cyclophosphamide (FC) regimen was reported to be superior to chlorambucil or fl...
Background: Fluadarabine (FLU) is a new antimetabolite chemotherapeutic agent with a promising thera...
BACKGROUND: Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with a promising therap...
BACKGROUND. A prospective, single-arm, open-label, nonrandomized Phase 2 study of combined fludarabi...
Purpose: In the last years, fludarabine (FLU) alone or in combination with other drugs has been repo...
The current study was conducted to asses the safety profile and clinical activity of rituximab in co...
Indolent non-Hodgkin lymphomas (iNHLs) are B-cell neoplasms for which no consensus is available abou...